Impact of Peptides and Chelators on Somatostatin Receptor Antagonists

NCT04491851 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DIAGNOSTIC_TEST: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT
DIAGNOSTIC_TEST: 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT

Sponsor

Peking Union Medical College Hospital